stockrowUFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
- Revenue
- +11.6%
- EPS
- +25.6%
- Free cash flow
- −35.8%
- Total debt
- −40.2%
Quarter to September 2026, against a year earlier
Follow UFPT
Alert me
UFP Technologies, Inc. (UFPT) Revenue
UFP Technologies, Inc.'s revenue for fiscal 2025 was $602.8M, up 19.5% from $504.4M in fiscal 2024. Over the twelve months to 30 September 2026 it was $649.5M. Over the past ten years it has ranged from $138.9M (fiscal 2015) to $602.8M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. UFP Technologies, Inc. ranks 37th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $602.8M | 19.50% |
| FY2024 | $504.4M | 26.08% |
| FY2023 | $400.1M | 13.08% |
| FY2022 | $353.8M | 71.48% |
| FY2021 | $206.3M | 15.02% |
| FY2020 | $179.4M | (9.58%) |
| FY2019 | $198.4M | 4.16% |
| FY2018 | $190.5M | 28.82% |
| FY2017 | $147.8M | 1.17% |
| FY2016 | $146.1M | 5.24% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $172.4M | (0.88%) |
| Jun 2026 | $174.0M | 12.82% |
| Mar 2026 | $154.2M | 3.55% |
| Dec 2025 | $148.9M | (3.65%) |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| NEOG Neogen Corporation compare | $884.0M |
| INSP Inspire Medical Systems, Inc. compare | $880.9M |
| TMDX TransMedics Group, Inc. compare | $727.7M |
| NVCR NovoCure Limited compare | $725.4M |
| UFPT UFP Technologies, Inc. | $649.5M |
| AXGN AxoGen, Inc. compare | $266.9M |
| ESTA Establishment Labs Holdings Inc. compare | $245.8M |
| BFLY Butterfly Network, Inc. compare | $123.3M |
| ALMR Alamar Biosciences, Inc. compare | $105.2M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on UFPT
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement